M. Reis

Articles by M. Reis

In Vivo Purging With Rituximab Prior to Stem Cell Collection Is Associated With Persistent Molecular Evidence of t(14;18) That Often Disappears Post-Transplant in Patients With Follicular Lymphoma

ByR. J. Buckstein,K. Imrie,D. Spaner,L. Bordeleau,T. Tompkins,E. Iakhnina,N. Pennell,A. Coovadia,M. Reis,K. Hewitt,P. Richardson,A. Lima,J. B. Robinson,M. Lim,B. Ordonez-Perez,N. L. Berinstein

March 1st 2000

We previously reported that “in vivo purging” with rituximab (Rituxan) during stem-cell collection is safe and does not adversely affect engraftment. We now report on our transplant experience with rituximab. From June 1998 to December

Latest Updated Articles

In Vivo Purging With Rituximab Prior to Stem Cell Collection Is Associated With Persistent Molecular Evidence of t(14;18) That Often Disappears Post-Transplant in Patients With Follicular Lymphoma
Published: March 1st 2000 | Updated:

M. Reis

Articles by M. Reis

In Vivo Purging With Rituximab Prior to Stem Cell Collection Is Associated With Persistent Molecular Evidence of t(14;18) That Often Disappears Post-Transplant in Patients With Follicular Lymphoma

Latest Updated Articles

Trending on CancerNetwork

Serplulimab Plus Chemo Meets EFS End Point in Early-Stage Gastric Cancer

CD20 Bispecifics vs CAR T: Evaluating CRS and ICANS in Lymphoma

KRd-Based Quadruplets May “Eliminate” Transplant Need for Multiple Myeloma

Clinical Implications and Future Directions

KRd Appears to Exhibit Greater Outcomes in Standard-Risk Multiple Myeloma